Observational studyActa neurologica Belgica2022
Indomethacin for refractory COVID or post-COVID headache: a retrospective study.
Observational study in Acta neurologica Belgica, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 43 citations in OpenAlex.
- Headache Management in the Neuroscience Intensive Care Unit.Current pain and headache reports · 2024Review
- [Interdisciplinary multimodal pain therapy in postviral syndromes and ME/CFS : Features, pitfalls and model concept].Schmerz (Berlin, Germany) · 2024Review
- Health equity, care access and quality in headache - part 1.The journal of headache and pain · 2024Review
- CGRP Antagonism and Ketogenic Diet in the Treatment of Migraine.Medicina (Kaunas, Lithuania) · 2024Review
- Persisting Shadows: Unraveling the Impact of Long COVID-19 on Respiratory, Cardiovascular, and Nervous Systems.Infectious disease reports · 2023Review
- Headache in COVID-19 and Long COVID: to Know Facts for Clinical Practice.Current neurology and neuroscience reports · 2023Review
- Indole-Based Compounds as Potential Drug Candidates for SARS-CoV-2.Molecules (Basel, Switzerland) · 2023Review
- Secondary headaches - red and green flags and their significance for diagnostics.eNeurologicalSci · 2023Review
- [Headache associated with COVID-19 vaccination: how to classify?]Schmerz (Berlin, Germany) · 2023Article
- Neuropsychiatric aspects of long COVID: A comprehensive review.Psychiatry and clinical neurosciences · 2023Review
- Headache in Post-COVID-19 Patients: Its Characteristics and Relationship with the Quality of Life.Medicina (Kaunas, Lithuania) · 2022Article
- Sex-dependent characteristics of Neuro-Long-COVID: Data from a dedicated neurology ambulatory service.Journal of the neurological sciences · 2022Article
- Therapeutic Approaches to the Neurologic Manifestations of COVID-19.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2022Article
- Long COVID headache.The journal of headache and pain · 2022Review
- In-silico screening and in-vitro assay show the antiviral effect of Indomethacin against SARS-CoV-2.Computers in biology and medicine · 2022Article
- Headache associated with COVID-19: Epidemiology, characteristics, pathophysiology, and management.Headache · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCOVID-19, a disease caused by SARS-CoV-2, manifests with headache, both in the acute phase and as a post-infection symptom, which may be refractory to usual analgesics.
objectivesInvestigate the therapeutic response of refractory COVID or post-COVID headache to indomethacin.
methodsThis was an observational, retrospective, open and uncontrolled. A sample of 37 patients diagnosed with COVID-19 presenting headache during the acute phase or after the resolution of the disease, with refractoriness to the usual symptomatic medication was treated with indomethacin.
resultsOf the 37 patients (24 women and 13 men), 29 were migraineurs and 8 had no previous history of headache. The average age was 40.4 ± 9.4 years, ranging from 19 to 65 years. In 26 (70.3%) patients, the onset of headache occurred within 72 h, and in 11 (29.7%), after 10 days of positivity for Sars-CoV-2. After treatment with indomethacin, 36 patients reported greater than 50% headache relief from the third day and 5 became asymptomatic on the fifth day.
conclusionsIn patients with migraine or no prior history of headache who present with refractory COVID or post-COVID headache to common analgesics, anti-inflammatory drugs, and/or triptans, indomethacin should be considered a therapeutic option.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.